Siglec transgenic mice and methods of use thereof
US11147249B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2017 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Mar 15, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/03
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.